Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELI(E)VE trial of belantamab mafodotin plus venetoclax in relapsed or refractory t(11;14) multiple myeloma
2024-511794-30-00Phase 2Authorised
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Jun 2023
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of belantamab mafodotin and venetoclax in multiple myeloma (MM), sponsored by University Medical Center Hamburg-Eppendorf. Planned start Jun 2023; status: authorised.
02
Drugs
belantamab mafodotinvenetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-511794-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511794-30-00.